Thursday, November 21, 2024
Home Tags Ctxr

Tag: ctxr

Citius, Leonard Mazur
2020 Watch List

Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.

Editor / Curator -
Citius
Biotech News

Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise...

Editor / Curator -
Citius, Biotech Stock Review
2020 Watch List

Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.

Editor / Curator -
Biotech News

Make Hay While the Sun Shines. Up 6,400%.

Editor / Curator -
Stem Cells

Heads Up! Big News on Stem Cells & Covid This Weekend.

Editor / Curator -
cITIUS
2020 Watch List

Citius (CTXR) Announces Results of Mino-Lok Study.

Editor / Curator -
Issam Radd
2020 Watch List

Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.

Editor / Curator -
Interview

Citius Pharma (CTXR) Video Presentation.

Editor / Curator -
citius pharma, biotech stock review
2020 Watch List

Investors Bet $8 Million on Citius Pharma (CTXR) $1.10, Succeeding in...

Editor / Curator -
Biotech News

Where is Citius Pharma (CTXR) in the FDA Approval Process?

Editor / Curator -
1234Page 2 of 4

Latest article

Nine Page Summary Report on GeoVax (GOVX)

2024 Watch List Editor / Curator -
This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

GeoVax (GOVX) Provides First Half 2024 Business Update.

2024 Watch List Editor / Curator -
Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

All News Editor / Curator -
Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: [email protected]
© Managed by Revelers.IO Media Group Inc.